Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Endostatin Adenovirus + PD-1 Inhibitor in H&N and Esophageal Cancer
NCT07154108Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Recombinant human endostatin adenovirus in head and neck cancer (HNC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan University. Primary endpoints: Incidence of treatment-related adverse effects and Incidence of Dose-Limiting Toxicities. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Recombinant human endostatin adenovirus
03
Conditions
head and neck cancer (HNC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07154108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154108.